News

Charles River spends $212M to beef up its microbial testing

Preclinical CRO Charles River Laboratories is paying $212 million in cash to buy a company focused on quality-control testing, expanding its presence in the market for bacterial detection services.

BioClinica buys a patient recruitment firm to bolster study startup

CRO BioClinica inked a deal to acquire MediciGroup, a patient recruitment and retention outfit that uses technology to keep subjects engaged in trials and minimize dropouts.

Quintiles and Quest unveil their clinical trials joint venture

Quintiles and Quest Diagnostics rolled out Q2 Solutions, a $575 million joint venture that pairs the CRO's experience running studies with the latter company's expertise in lab tests.

GVK inks another R&D deal as it moves on from data scandal

GVK BioSciences, an Indian CRO under fire from European regulators, has signed a deal with Australia's Akaal Pharma to help the company move its in-development psoriasis treatment into mid-stage trials.

Covance joins trial site group to speed up R&D

Covance, now a division of LabCorp, has signed a two-year partnership with the Society for Clinical Research Sites, joining a growing list of CROs working to improve communication between sponsors and investigators.

PPD strings together a site network for pediatric trials

PPD, angling to stand out among CROs running pediatric trials, has cemented a network of 8 global sites to accelerate the process of starting studies on kids.

BioClinica expands in Europe with a focus on imaging

CRO BioClinica has opened new outposts in the U.K. and Germany, expanding its European footprint and scaling up its capabilities in medical imaging.

Novasep bets $11M on armed antibody R&D

French contract drugmaker Novasep is investing €10 million ($11 million) to build an antibody-drug conjugate facility at its Le Mans outpost.

PRA debuts a sweeping clinical trial operating system

PRA Health Sciences, a year removed from its $300 million IPO, unveiled an end-to-end technology platform that pools trial design, planning and monitoring in one place, touting its new offering as a major step forward for the CRO.

Icon rolls out some new patient-consent tech with a focus on education

Icon, at work on new approaches to educating potential study participants, launched a new technology designed to inform patients of the possible risks and benefits of a clinical trial before they meet with a physician.

Huntingdon and Harlan move forward under a new moniker

Huntingdon Life Sciences, a year removed from acquiring Harlan Laboratories, is changing the combined company's name to Envigo as it works to expand its presence on the CRO market.

Parexel cutting 850 jobs as it dims its revenue outlook

CRO giant Parexel is planning to shed about 850 jobs over the next year in an effort to cut costs as it lowers its financial expectations for the quarter.

Veristat reaches into the Bay Area with new outpost

Massachusetts CRO Veristat has cut the ribbon on its new West Coast base, opening a Bay Area operation in an effort to maintain its recent growth.

Quintiles beefs up its risk-based monitoring tech

Quintiles has rewired its risk-based monitoring service to include analytics technology the CRO says can better predict pressure points in clinical trials, touting its new offering as the first of its kind.

AMRI recruits PerkinElmer to build out a new R&D hub

AMRI, in the process of consolidating its drug discovery services, is teaming up with life sciences giant PerkinElmer to accelerate a new biomedical hub in Buffalo, NY.

Recipharm snags a chemistry-focused CRO amid buyout push

Swedish drug developer Recipharm bought a local CRO for 15.1 million kronor ($6.2 million), fleshing out its chemistry services as it works to expand its share of the European market.

GVK inks a deep biotech deal as it rebuilds its reputation

India's GVK BioSciences, marred by a data scandal, has signed an exclusive deal with Swedish drug developer Medivir, agreeing to handle the bulk of the biotech's chemistry work.

PPD partners up for real-world outcomes research

As regulators and payers place increasing importance on real-world data, CRO PPD is working to expand its reach in the field, joining forces with a division of insurance giant Anthem.

ContraVir recruits CRO ImageIQ for shingles trial

Antiviral drug developer ContraVir Pharmaceuticals is working with ImageIQ on its Phase III program for a new shingles treatment, tapping the company for its imaging expertise.

TFS takes the plunge on a risk-sharing deal for a Parkinson's drug

Swedish CRO TFS is working with local biotech LobSor Pharmaceuticals on a new treatment for Parkison's disease, agreeing to share the risks and potential rewards of the development process.